Canada - English - Health Canada

efamol research inc. - cis-linoleic acid (evening primrose oil); gamma-linolenic acid (evening primrose oil); calcium (calcium carbonate); d-alpha tocopheryl acetate - capsule - 255mg; 30mg; 100mg; 13.6unit - cis-linoleic acid (evening primrose oil) 255mg; gamma-linolenic acid (evening primrose oil) 30mg; calcium (calcium carbonate) 100mg; d-alpha tocopheryl acetate 13.6unit - vitamins & minerals

Canada - English - Health Canada

efamol research inc. - cis-linoleic acid (evening primrose oil); gamma-linolenic acid (evening primrose oil); dl-alpha tocopheryl acetate - capsule - 108mg; 13.5mg; 20unit - cis-linoleic acid (evening primrose oil) 108mg; gamma-linolenic acid (evening primrose oil) 13.5mg; dl-alpha tocopheryl acetate 20unit - vitamin e

Canada - English - Health Canada

efamol research inc. - cis-linoleic acid (evening primrose oil); gamma-linolenic acid (evening primrose oil); calcium (calcium carbonate); vitamin e (d-alpha tocopheryl acetate) - capsule - 255mg; 30mg; 100mg; 13.6unit - cis-linoleic acid (evening primrose oil) 255mg; gamma-linolenic acid (evening primrose oil) 30mg; calcium (calcium carbonate) 100mg; vitamin e (d-alpha tocopheryl acetate) 13.6unit - vitamins & minerals

Canada - English - Health Canada

wing quon enterprises ltd. - cis-linoleic acid (evening primrose oil); gamma-linolenic acid (evening primrose oil) - capsule - 375mg; 125mg - cis-linoleic acid (evening primrose oil) 375mg; gamma-linolenic acid (evening primrose oil) 125mg - other nutritional agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cisplatin 1 mg/ml;   - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - cisplatin accord injection is indicated for the palliative treatment of: · metastatic non-seminomatous germ cell carcinoma; · advanced-stage refractory ovarian carcinoma; · advanced-stage refractory bladder carcinoma; and · refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, e.g. radiotherapy or surgery.

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - cisplatin - concentrate for solution for infusion - cisplatin 1 mg - antineoplastic agents

Malta - English - Medicines Authority

hospira uk limited - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

hospira uk limited - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

hospira uk limited - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents